Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Sci Rep ; 11(1): 13022, 2021 06 22.
Article in English | MEDLINE | ID: mdl-34158575

ABSTRACT

Childhood obesity continues to escalate worldwide and may affect left ventricular (LV) geometry and function. The aim of this study was to investigate the impact of obesity on prevalence of left ventricular hypertrophy (LVH) and diastolic dysfunction in children. In this analysis of prospectively collected cross-sectional data of children between 5 and 16 years of age from randomly selected schools in Peru, parameters of LV geometry and function were compared according to presence or absence of obesity (body mass index z-score > 2). LVH was based on left ventricular mass index (LVMI) adjusted for age and sex and defined by a z-score of > 2. LV diastolic function was assessed using mitral inflow early-to-late diastolic flow (E/A) ratio, peak early diastolic tissue velocities of the lateral mitral annulus (E'), early diastolic transmitral flow velocity to tissue Doppler mitral annular early diastolic velocity (E/E') ratio, and left atrial volume index (LAVI). Among 1023 children, 681 children (mean age 12.2 ± 3.1 years, 341 male (50.1%)) were available for the present analysis, of which 150 (22.0%) were obese. LVH was found in 21 (14.0%) obese and in 19 (3.6%) non-obese children (padjusted < 0.001). LVMI was greater in obese than that in non-obese children (36.1 ± 8.6 versus 28.7 ± 6.9 g/m2.7, p < 0.001). The mean mitral E/E' ratio and LAVI were significantly higher in obese than those in non-obese individuals (E/E': 5.2 ± 1.1 versus 4.9 ± 0.8, padjusted = 0.043; LAVI 11.0 ± 3.2 versus 9.6 ± 2.9, padjusted = 0.001), whereas E' and E/A ratio were comparable. Childhood obesity was associated with left ventricular hypertrophy and determinants of diastolic dysfunction.ClinicalTrials.gov Identifier: NCT02353663.


Subject(s)
Diastole/physiology , Hypertrophy, Left Ventricular/complications , Hypertrophy, Left Ventricular/physiopathology , Obesity/complications , Obesity/physiopathology , Adolescent , Body Mass Index , Child , Female , Heart Ventricles/pathology , Heart Ventricles/physiopathology , Humans , Hypertrophy, Left Ventricular/pathology , Male , Myocardium/pathology , Obesity/pathology , Organ Size
2.
Arch Cardiol Mex ; 88(5): 403-412, 2018 12.
Article in Spanish | MEDLINE | ID: mdl-29305300

ABSTRACT

OBJECTIVE: To determine the epidemiological characteristics, treatment, reperfusion strategies and in-hospital adverse events of patients with ST elevation myocardial infarction in Peru. METHODS: Observational, prospective multicentre study in patients over 18 years admitted to hospital with a diagnosis of ST elevation myocardial infarction. RESULTS: A total of 396 patients were enrolled in the registry during February 2016 to February 2017. The mean age was 64.9±12 years, and 21% were women. In the first 12h of onset 38% of patients were fibrinolysed, 29% underwent primary PCI, and 33% did not receive any reperfusion. Pharmaco-invasive strategy was used in 12.9% of cases. The fibrinolysis was successful in 65% of patients, and primary PCI success was 82%. The hospital stay was 6 days (IQR 5-10). In-hospital mortality was 10.1%, with the first cause of death being due to cardiogenic shock. The rate of in-hospital re-infarction was 2.2%, and the rate of acute heart failure was 25%. Age>75 years, large infarct size, left ventricular ejection fraction<40%, and absence of negative T waves on post-reperfusion electrocardiogram were independently related to higher in-hospital mortality. CONCLUSIONS: In Peru, ST elevation myocardial infarction most frequently affects men between 60-70 years. The most frequent initial reperfusion treatment is fibrinolysis, followed by primary angioplasty, and pharmaco-invasive strategy. The main reason for the lack of administration of reperfusion treatment was the delay from symptoms onset to first medical contact. The most common cause of in-hospital death was cardiogenic shock.


Subject(s)
Heart Failure/epidemiology , Myocardial Reperfusion/methods , ST Elevation Myocardial Infarction/epidemiology , Shock, Cardiogenic/epidemiology , Adult , Aged , Aged, 80 and over , Electrocardiography , Female , Hospital Mortality , Humans , Male , Middle Aged , Peru , Prospective Studies , Registries , ST Elevation Myocardial Infarction/mortality , ST Elevation Myocardial Infarction/therapy , Shock, Cardiogenic/mortality , Treatment Outcome , Ventricular Function, Left
3.
Arch. cardiol. Méx ; 88(5): 403-412, dic. 2018. graf
Article in Spanish | LILACS | ID: biblio-1142150

ABSTRACT

Resumen Objetivo: Determinar las características epidemiológicas, el tratamiento, las estrategias de reperfusión y los eventos adversos intrahospitalarios de pacientes con infarto de miocardio con elevación del segmento ST en Perú. Métodos: Estudio observacional, prospectivo, multicéntrico a nivel nacional, en pacientes mayores de 18 años hospitalizados con diagnóstico de infarto de miocardio con elevación del segmento ST. Resultados: Desde febrero de 2016 a febrero de 2017, 396 pacientes fueron enrolados; la edad promedio fue de 64.9 ± 12 años y el 21% eran mujeres. En las primeras 12 h de evolución un 38% fueron fibrinolisados, en un 29% se realizó PCI primaria y un 33% no recibieron reperfusión. En el 12.9% se usó estrategia farmacoinvasiva. La tasa de éxito de la fibrinólisis fue de un 65% y la de la PCI primaria fue de un 82%. La estancia hospitalaria fue de 6 días (RIQ 5-10). La mortalidad intrahospitalaria llegó a un 10.1%, siendo la principal causa de muerte el choque cardiogénico. La tasa de reinfarto intrahospitalario fue de 2.2% y de falla cardiaca postinfarto, de 25%. La edad > 75 años, grandes tamaños de infarto, la fracción de eyección de ventrículo izquierdo < 40% y la ausencia de ondas T negativas en el electrocardiograma posreperfusión fueron variables relacionadas de manera independiente con una mayor mortalidad intrahospitalaria. Conclusiones: El infarto de miocardio con elevación del segmento ST en Perú afecta con más frecuencia a varones de entre 60 y 70 años. El tratamiento de reperfusión inicial más frecuente es la fibrinólisis, seguida por la angioplastia primaria y la estrategia farmacoinvasiva. El motivo principal de la falta de administración de tratamiento de reperfusión fue la demora desde el inicio de los síntomas hasta el primer contacto médico. La causa más frecuente de muerte intrahospitalaria es el choque cardiogénico.


Abstract Objective: To determine the epidemiological characteristics, treatment, reperfusion strategies and in-hospital adverse events of patients with ST elevation myocardial infarction in Peru. Methods: Observational, prospective multicentre study in patients over 18 years admitted to hospital with a diagnosis of ST elevation myocardial infarction. Results: A total of 396 patients were enrolled in the registry during February 2016 to February 2017. The mean age was 64.9 ± 12 years, and 21% were women. In the first 12 h of onset 38% of patients were fibrinolysed, 29% underwent primary PCI, and 33% did not receive any reperfusion. Pharmaco-invasive strategy was used in 12.9% of cases. The fibrinolysis was successful in 65% of patients, and primary PCI success was 82%. The hospital stay was 6 days (IQR 5-10). In-hospital mortality was 10.1%, with the first cause of death being due to cardiogenic shock. The rate of in-hospital re-infarction was 2.2%, and the rate of acute heart failure was 25%. Age > 75 years, large infarct size, left ventricular ejection fraction < 40%, and absence of negative T waves on post-reperfusion electrocardiogram were independently related to higher in-hospital mortality. Conclusions: In Peru, ST elevation myocardial infarction most frequently affects men between 60-70 years. The most frequent initial reperfusion treatment is fibrinolysis, followed by primary angioplasty, and pharmaco-invasive strategy. The main reason for the lack of administration of reperfusion treatment was the delay from symptoms onset to first medical contact. The most common cause of in-hospital death was cardiogenic shock.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Shock, Cardiogenic/epidemiology , Myocardial Reperfusion/methods , ST Elevation Myocardial Infarction/epidemiology , Heart Failure/epidemiology , Peru , Registries , Prospective Studies , Ventricular Function, Left , Treatment Outcome , Hospital Mortality , Electrocardiography
4.
PLoS One ; 10(7): e0133004, 2015.
Article in English | MEDLINE | ID: mdl-26208006

ABSTRACT

BACKGROUND: The objective of the study was to evaluate the implications of different classifications of rheumatic heart disease on estimated prevalence, and to systematically assess the importance of incidental findings from echocardiographic screening among schoolchildren in Peru. METHODS: We performed a cluster randomized observational survey using portable echocardiography among schoolchildren aged 5 to 16 years from randomly selected public and private schools in Arequipa, Peru. Rheumatic heart disease was defined according to the modified World Health Organization (WHO) criteria and the World Heart Federation (WHF) criteria. FINDINGS: Among 1395 eligible students from 40 classes and 20 schools, 1023 (73%) participated in the present survey. The median age of the children was 11 years (interquartile range [IQR] 8-13 years) and 50% were girls. Prevalence of possible, probable and definite rheumatic heart disease according to the modified WHO criteria amounted to 19.7/1000 children and ranged from 10.2/1000 among children 5 to 8 years of age to 39.8/1000 among children 13 to 16 years of age; the prevalence of borderline/definite rheumatic heart disease according to the WHF criteria was 3.9/1000 children. 21 children (2.1%) were found to have congenital heart disease, 8 of which were referred for percutaneous or surgical intervention. CONCLUSIONS: Prevalence of RHD in Peru was considerably lower compared to endemic regions in sub-Saharan Africa, southeast Asia, and Oceania; and paralleled by a comparable number of undetected congenital heart disease. Strategies to address collateral findings from echocardiographic screening are necessary in the setup of active surveillance programs for RHD. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02353663.


Subject(s)
Mass Screening , Rheumatic Heart Disease/epidemiology , Adolescent , Anthropometry , Antibiotic Prophylaxis , Child , Child, Preschool , Female , Health Surveys , Heart Defects, Congenital/diagnostic imaging , Heart Defects, Congenital/epidemiology , Humans , Incidental Findings , Male , Observer Variation , Peru/epidemiology , Physical Examination , Prevalence , Rheumatic Heart Disease/diagnostic imaging , Sampling Studies , Socioeconomic Factors , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...